Efficacy of COVID-19 treatments: a Bayesian network meta-analysis of randomized controlled trials

C Zhang, H Jin, YF Wen, G Yin - Frontiers in Public Health, 2021 - frontiersin.org
Background: We provided a comprehensive evaluation of efficacy of available treatments for
coronavirus disease 2019 (COVID-19). Methods: We searched for candidate COVID-19 …

Renin‐angiotensin aldosterone system inhibitors and COVID‐19: a systematic review and meta‐analysis revealing critical bias across a body of observational …

J Loader, FC Taylor, E Lampa… - Journal of the American …, 2022 - Am Heart Assoc
Background Renin‐angiotensin aldosterone system (RAAS) inhibitor—COVID‐19 studies,
observational in design, appear to use biased methods that can distort the interaction …

Angiotensin-Converting Enzyme (ACE) level, but not ACE gene polymorphism, is associated with prognosis of COVID-19 infection: Implications for diabetes and …

O Elbasan, F Bayram, CD Yazan, T Apaydın… - PloS one, 2023 - journals.plos.org
Background The renin-angiotensin-aldosterone system was shown to be activated in severe
COVID-19 infection. We aimed to investigate the relationship between angiotensin …

Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double …

G Tornling, R Batta, JC Porter, B Williams… - …, 2021 - thelancet.com
Background COVID-19 morbidity and mortality remains high and the need for safe and
effective drugs continues despite vaccines. Methods Double-blind, placebo-controlled, multi …

Atherosclerosis, cardiovascular disease, and COVID-19: a narrative review

C Vilaplana-Carnerero, M Giner-Soriano, À Dominguez… - Biomedicines, 2023 - mdpi.com
Atherosclerosis is a chronic inflammatory and degenerative process that mainly occurs in
large-and medium-sized arteries and is morphologically characterized by asymmetric focal …

Effects of renin–angiotensin system inhibitors on mortality and disease severity of COVID-19 patients: a meta-analysis of randomized controlled trials

J Yin, C Wang, X Song, X Li… - American Journal of …, 2022 - academic.oup.com
BACKGROUND There is controversy over the effects of angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on the prognosis in patients …

Renin–angiotensin–aldosterone inhibitors and COVID-19 infection

V Tsampasian, N Corballis, VS Vassiliou - Current Hypertension Reports, 2022 - Springer
Abstract Purpose of Review This review summarises the literature data and provides an
overview of the role and impact of the use of renin–angiotensin–aldosterone system (RAAS) …

Impact of renin–angiotensin–aldosterone system inhibitors on COVID-19

Y Matsuzawa, K Kimura, H Ogawa, K Tamura - Hypertension Research, 2022 - nature.com
Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, the possible roles of
renin–angiotensin system (RAS) inhibitors in COVID-19 have been debated as favorable …

Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials

IG Asiimwe, SP Pushpakom, RM Turner… - British journal of …, 2022 - Wiley Online Library
Aims: To update our previously reported systematic review and meta‐analysis of
observational studies on cardiovascular drug exposure and COVID‐19 clinical outcomes by …

Renin–angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease

MP Theodorakopoulou, ME Alexandrou… - Clinical kidney …, 2022 - academic.oup.com
Hypertension and chronic kidney disease (CKD) are among the most common comorbidities
associated with coronavirus disease 2019 (COVID-19) severity and mortality risk. Renin …